Dataset:21122225 Search Result
Clinical Information
Characteristics of 10 patients infected with oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea, 2009
Patient	Age, y/ sex	Antiviral treatment and date	Date of specimen collection	Type of clinical specimen	Underlying condition
A	5/M	Oseltamivir, 30 mg 2×/d (Oct 29–Nov 4); 60 mg 2×/d (Nov 5–9)	6-Nov	Nasopharyngeal swab	Mitochondrial cytopathic changes (bedridden)
B	46/M	Oseltamivir, 150 mg 2×/d (Nov 6–15); zanamivir, 10 mg 2×/d (Nov 16–26)	18-Nov	Nasopharyngeal swab	Leukemia
C	1/F	Oseltamivir, 30 mg 2×/d (Nov 16–21); 60 mg 2×/d (Nov 22–Dec 8)	Nov 21 and 22	Nasopharyngeal swab	Brain damage (fatal)
D	2/M	Oseltamivir, 90 mg 2×/d (Nov 26–30); 180 mg and amantadine, 65 mg 2×/d (Dec 2–7)	Nov 22, Dec 2	Nasal suction	None
E	3/F	Oseltamivir, 30 mg 2×/d (Dec 1–5 and 7–11)	Dec 1, 7, and 9	Oropharyngeal swab (Dec 1, 7); nasopharyngeal swab (Dec 9)	Asthma
F	3/F	Oseltamivir, 45 mg 2×/d (Dec 10–15); 75 mg 2×/d (Dec 16–20)	18-Dec	Oropharyngeal swab	Delayed development
G	1/F	Oseltamivir, 30 mg 2×/d (Dec 1–5); peramivir, 75 mg 1×/day (Dec 12–18)	Dec 1, 5, and 15	Nasal/oropharyngeal swab	Myelodysplasia (fatal)
H	63/M	Oseltamivir, 150 mg 2×/d (Dec 7–15); zanamivir, 10 mg 2×/d (Dec 16–20)	16-Dec	Oropharyngeal swab	Diabetes
I	58/M	Oseltamivir, 150 mg 2×/d (Dec 16–18); peramivir, 600 mg 1×/d, amantadine, 100 mg 2×/d a day, ribavirin, 300 mg 1×/d (Dec 19–25); zanamivir, 10 mg 2×/d (Dec 26–2010 Jan 1)	26-Dec	Nasopharyngeal swab	Cancer
J	60/M	Oseltamivir, 75 mg 2×/d (Nov 30–Dec 2)	1-Dec	Viral RNA	Diabetes, cardiac disorders (fatal)